Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?
作者信息
Romão Vasco C, Fonseca João Eurico
机构信息
Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal.
Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
出版信息
Front Med (Lausanne). 2019 Jun 26;6:144. doi: 10.3389/fmed.2019.00144. eCollection 2019.
Abstract
摘要
相似文献
1
Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?风湿病学的主要挑战：我们能否更明智地治疗，而非仅仅加大治疗力度？
Front Med (Lausanne). 2019 Jun 26;6:144. doi: 10.3389/fmed.2019.00144. eCollection 2019.
2
How advances in personalized medicine will change rheumatology.个性化医疗的进展将如何改变风湿病学。
Per Med. 2018 Mar;15(2):75-78. doi: 10.2217/pme-2017-0079. Epub 2018 Feb 2.
3
Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.疾病修饰抗风湿药物在类风湿关节炎中的药物遗传学：迈向个体化医学。
Pharmacogenomics. 2013 Mar;14(4):425-44. doi: 10.2217/pgs.13.22.
4
APLAR rheumatoid arthritis treatment recommendations.亚太风湿病学联盟类风湿关节炎治疗建议。
Int J Rheum Dis. 2015 Sep;18(7):685-713. doi: 10.1111/1756-185X.12754.
5
The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network.类风湿关节炎达标治疗试验：Corrona风湿病网络内的一项整群随机试验。
BMC Musculoskelet Disord. 2014 Nov 21;15:389. doi: 10.1186/1471-2474-15-389.
6
Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers.解读中重度类风湿性关节炎的临床试验结果：对风湿病医疗服务提供者的实际应用
J Am Acad Nurse Pract. 2011 Sep;23(9):479-92. doi: 10.1111/j.1745-7599.2011.00665.x.
7
Rheumatoid arthritis patients' education - contents and methods.类风湿关节炎患者教育——内容与方法
J Clin Nurs. 2007 Nov;16(11C):258-67. doi: 10.1111/j.1365-2702.2007.01953.x.
8
Magnetic Resonance Imaging in Rheumatology.风湿病学中的磁共振成像
Magn Reson Imaging Clin N Am. 2018 Nov;26(4):599-613. doi: 10.1016/j.mric.2018.06.008.
9
Overdiagnosis and overtreatment in rheumatology: a little caution is in order.风湿学中的过度诊断和过度治疗：谨慎行事是必要的。
Ann Rheum Dis. 2018 Oct;77(10):1394-1396. doi: 10.1136/annrheumdis-2018-213700. Epub 2018 Jul 4.
10
[Rheumatology (rheumatoid arthritis, psoriatic arthritis, Spondyloarthritis): What are the most important innovations in the last 10 years?].[风湿病学（类风湿性关节炎、银屑病关节炎、脊柱关节炎）：过去10年最重要的创新成果有哪些？]
MMW Fortschr Med. 2018 Nov;160(Suppl 3):50-54. doi: 10.1007/s15006-018-1122-8.
引用本文的文献
1
Negotiating Professional Tasks in a Hospital: A Qualitative Study of Rheumatologists and Occupational Therapists in the Management of Hand Osteoarthritis.医院中专业任务的协商：一项关于风湿病学家和职业治疗师对手部骨关节炎管理的定性研究
J Multidiscip Healthc. 2023 Oct 18;16:3057-3074. doi: 10.2147/JMDH.S425640. eCollection 2023.
2
A novel 3D spheroid model of rheumatoid arthritis synovial tissue incorporating fibroblasts, endothelial cells, and macrophages.一种新型的类风湿关节炎滑膜组织的 3D 球体模型，包含成纤维细胞、内皮细胞和巨噬细胞。
Front Immunol. 2023 Jul 20;14:1188835. doi: 10.3389/fimmu.2023.1188835. eCollection 2023.
3
Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment: An Individual Participant Data Meta-Analysis.估算生物制剂加入常规类风湿关节炎治疗对患者个体获益的影响：一项个体参与者数据的荟萃分析。
JAMA Netw Open. 2023 Jun 1;6(6):e2321398. doi: 10.1001/jamanetworkopen.2023.21398.
4
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP.阿巴西普与托法替布对类风湿关节炎抗环瓜氨酸肽抗体阳性患者的疗效比较
Rheumatol Ther. 2023 Jun;10(3):575-587. doi: 10.1007/s40744-022-00523-z. Epub 2023 Feb 7.
5
Editorial: Insights in Rheumatology: 2021.社论：风湿病学见解：2021年。
Front Med (Lausanne). 2022 Jul 22;9:971777. doi: 10.3389/fmed.2022.971777. eCollection 2022.
6
Nutrition and Rheumatoid Arthritis Onset: A Prospective Analysis Using the UK Biobank.营养与类风湿关节炎发病：基于英国生物库的前瞻性分析。
Nutrients. 2022 Apr 8;14(8):1554. doi: 10.3390/nu14081554.
7
Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis.关注性别：类风湿关节炎管理中我们需要了解的内容。
J Pers Med. 2022 Mar 20;12(3):499. doi: 10.3390/jpm12030499.
8
Non-invasive monitoring of arthritis treatment response via targeting of tyrosine-phosphorylated annexin A2 in chondrocytes.通过靶向软骨细胞中酪氨酸磷酸化的膜联蛋白 A2 来进行关节炎治疗反应的无创监测。
Arthritis Res Ther. 2021 Oct 25;23(1):265. doi: 10.1186/s13075-021-02643-3.
9
Identification of Compounds With Glucocorticoid Sparing Effects on Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-Like Synoviocytes.鉴定对类风湿性关节炎成纤维样滑膜细胞趋化因子和细胞因子产生抑制具有糖皮质激素节省效应的化合物。
Front Pharmacol. 2020 Dec 17;11:607713. doi: 10.3389/fphar.2020.607713. eCollection 2020.
本文引用的文献
1
Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases.从专利生物药转换为生物类似药：免疫介导的炎症性疾病的当前观点。
Expert Opin Biol Ther. 2019 Oct;19(10):1001-1014. doi: 10.1080/14712598.2019.1610381. Epub 2019 May 6.
2
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.JAK激酶抑制剂治疗类风湿关节炎的比较：一项系统文献综述
Immunotherapy. 2019 Jun;11(8):737-754. doi: 10.2217/imt-2018-0178. Epub 2019 Apr 8.
3
Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study.英国类风湿关节炎患者症状出现与首次风湿病就诊之间的延误：一项观察性研究。
BMJ Open. 2019 Mar 4;9(3):e024361. doi: 10.1136/bmjopen-2018-024361.
4
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.JAK 抑制剂在类风湿关节炎中的临床疗效。
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i17-i26. doi: 10.1093/rheumatology/key225.
5
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.风湿学中的未满足需求：2018 年靶向治疗会议报告。
Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2.
6
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.是否切换：全国强制性从原研药切换至生物类似药依那西普的指南结果。DANBIO 登记处 2061 例炎性关节炎患者的 1 年治疗结果。
Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5.
7
Overdiagnosis and overtreatment in rheumatology: a little caution is in order.风湿学中的过度诊断和过度治疗：谨慎行事是必要的。
Ann Rheum Dis. 2018 Oct;77(10):1394-1396. doi: 10.1136/annrheumdis-2018-213700. Epub 2018 Jul 4.
8
Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis.影响弥漫性皮肤系统性硬化症患者早期转介、早期诊断和治疗的因素。
Rheumatology (Oxford). 2018 May 1;57(5):813-817. doi: 10.1093/rheumatology/kex504.
9
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.避免抗中性粒细胞胞浆抗体相关性血管炎治疗带来的伤害。
Curr Treatm Opt Rheumatol. 2017;3(4):230-243. doi: 10.1007/s40674-017-0082-y. Epub 2017 Nov 13.
10
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?正确的药物、正确的患者、正确的时间：生物制剂在类风湿关节炎中的应用前景如何？
Arthritis Res Ther. 2017 Oct 24;19(1):239. doi: 10.1186/s13075-017-1445-3.
Zotero 插件